Avantor (AVTR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Avantor, Inc. reported $1.71 billion in revenue for Q3 2024, reflecting a year-over-year decline of 0.3% [1] - The company's EPS for the same period was $0.26, compared to $0.25 a year ago, indicating a slight improvement [1] - Revenue fell short of the Zacks Consensus Estimate of $1.72 billion, resulting in a surprise of -0.57% [1] - The EPS exceeded the consensus estimate of $0.25, delivering a surprise of +4.00% [1] Revenue Breakdown - Bioscience Production revenue was $542.90 million, below the average estimate of $550.65 million from four analysts [2] - Laboratory Solutions revenue matched the estimate at $1.17 billion [2] Operating Income Analysis - Adjusted Operating Income for Laboratory Solutions was $151.50 million, compared to the average estimate of $155.83 million [2] - Adjusted Operating Income for Corporate was -$14.80 million, better than the average estimate of -$17.46 million [2] - Adjusted Operating Income for Bioscience Production was $138.10 million, below the average estimate of $143.89 million [2] Stock Performance - Avantor's shares have declined by 10.7% over the past month, while the Zacks S&P 500 composite increased by 1.4% [2] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [2]